Xtant Medical Holdings, Inc. (NASDAQ:XTNT) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
The Company has issued a press release on November 15, 2016,
entitled Xtant Medical Receives FDA Clearance to Use Allografts
in the Stand-Alone Irix-C Cervical Cage, which is attached as
Exhibit 99.1 and incorporated herein.
The Company has also issued a press release on November 15, 2016,
entitled Xtant Medical Announces Expiration of Rights Offering
and Estimated Gross Proceeds of $3.8 Million, which is attached
as Exhibit 99.2 and incorporated herein.
The information in this Item 7.01 and the documents attached as
Exhibits 99.1 and 99.2 are being furnished and shall not be
deemed filed for purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended (the Exchange Act), nor
otherwise subject to the liabilities of that section, nor
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as shall be expressly set
forth by specific reference in such filings.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | |
| 99.1 |
Press Release of Xtant Medical Holdings, Inc. dated |
|
| 99.2 |
Press Release of Xtant Medical Holdings, Inc. dated November 15, 2016 entitled Xtant Medical Announces Expiration of Rights Offering and Estimated Gross Proceeds of $3.8 Million. |
About Xtant Medical Holdings, Inc. (NASDAQ:XTNT)
